替格瑞洛相关呼吸困难的危险因素研究进展  

Research progress on risk factors of Ticagrelor-related dyspnea

作　　者：赵一帆 康煜 孙珂 邵静[1] ZHAO Yifan;KANG Yu;SUN Ke;SHAO Jing(Department of Geriatric Diseases,the First Affiliated Hospital of Henan University of Chinese Medicine,Henan Province,Zhengzhou450099,China)

机构地区：[1]河南中医药大学第一附属医院老年病科,河南郑州450099

出　　处：《中国医药导报》2024年第30期70-73,共4页China Medical Herald

摘　　要：替格瑞洛是新一代P2Y12受体拮抗剂,在急性冠脉综合征患者中具有良好的抗血小板聚集效果和安全性。然而,在服用替格瑞洛时,可出现呼吸困难、出血等不良反应,其中呼吸困难的发生率>10%。替格瑞洛引起的呼吸困难,可影响患者的药物依从性,导致提前停药,从而使缺血事件的风险增加。明确替格瑞洛相关呼吸困难的危险因素,对提高依从性、避免缺血事件发生(如支架内血栓形成等)及改善远期预后具有重大的临床意义。本文系统综述了替格瑞洛相关呼吸困难的危险因素,旨在为此不良反应的早期预防及合理用药提供参考。Ticagrelor is a new-generation P2Y12 receptor antagonist with favorable antiplatelet aggregation efficacy and safety profile in patients with acute coronary syndromes.However,adverse reactions such as dyspnea and bleeding can occur when taking Ticagrelor,with the incidence of dyspnea being>10%.Ticagrelor-related dyspnea can affect patients’drug adherence and lead to early discontinuation of the drug,thus increasing the risk of ischemic events.Defining the risk factors for respiratory distress related to Ticagrelor is of great clinical significance for improving adherence,avoiding ischemic events(such as in-stent thrombosis),and improving long-term prognosis.In this article,we systematically review the risk factors for Ticagrelor-related dyspnea,with the aim of providing a reference for the early prevention of this adverse effect and the rational use of medication.

关 键 词：替格瑞洛 呼吸困难 危险因素 

分 类 号：R973[医药卫生—药品]